Tarek Bismar

Dr. Bismar is currently a Professor at the University of Calgary and Adjunct Professor in the Department of Oncology at McGill University. While he was at McGill University, his service achievement is the establishment and participation of Urological Oncology Rounds at the Jewish General Hospital, as well as working as the primary pathologist for signing out genitourinary oncology cases. He was also a consultant for genitourinary pathology and oncology cases for various department members. His research achievements include the directorship and establishment of the tissue microarray facility at the Lady Davis Institute with the support of Dr. Gerald Batist.  His accomplishments also include the establishment of several tissue micorarrays for prostate cancer with detailed clinical and pathological outcomes. These arrays were the first at McGill University and Dr. Bismar has been utilizing them for various collaborations with several investigators in the Department of Oncology. The use of these arrays has lead to a number of publications and grant submissions with members of the Department of Oncology.

Dr. Bismar is still actively involved in several collaborations with members of the Department of Oncology at McGill University and also supports translational research in the fields of breast and prostate cancer. To date, these collaborations have generated more than 7 papers with several others forthcoming. These collaborative studies have been published in several high impact journals, including Journal of Experimental Medicine, Cancer Research and Clinical Cancer Research. Dr. Bismar’s efforts also support various department members in securing external funds through the addition of his expertise in utilizing high throughput tissue microarrays to support basic science proposals. Dr. Bismar’s active collaborators include Drs. Moulay Alaoi-Jamali, Mark Trifiro, John White, and William Foulkes. They have also included Dr. Gerald Batist, Ala-Eldin Almostafa and Mark Basik.

Dr. Bismar’s research accomplishments are not only impacting investigators at McGill University, but also across Canada, the USA and internationally. His various TMAs are being interrogated for various biomarkers related to cancer progression. In addition, Dr. Bismar’s recent achievement of identifying a 10 gene multi-model with prognostic implication is another example of the added benefits of his research to the community.

Cancer biomarkers, gene expression, proteomics